Cargando…
Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy
Heart failure is one of the most common chronic medical conditions in the developed world. It is characterized by neurohormonal activation of multiple systems that can lead to clinical deterioration and significant morbidity and mortality. In this regard, hyponatremia is due to inappropriate and con...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3097052/ https://www.ncbi.nlm.nih.gov/pubmed/21603106 http://dx.doi.org/10.4061/2011/732746 |
_version_ | 1782203784198356992 |
---|---|
author | Romanovsky, Adam Bagshaw, Sean Rosner, Mitchell H. |
author_facet | Romanovsky, Adam Bagshaw, Sean Rosner, Mitchell H. |
author_sort | Romanovsky, Adam |
collection | PubMed |
description | Heart failure is one of the most common chronic medical conditions in the developed world. It is characterized by neurohormonal activation of multiple systems that can lead to clinical deterioration and significant morbidity and mortality. In this regard, hyponatremia is due to inappropriate and continued vasopressin activity despite hypoosmolality and volume overload. Hyponatremia is also due to diuretic use in an attempt to manage volume overload. When hyponatremia occurs, it is a marker of heart failure severity and identifies patients with increased mortality. The recent introduction of specific vasopressin-receptor antagonists offers a targeted pharmacological approach to these pathophysiological derangements. Thus far, clinical trials with vasopressin-receptor antagonists have demonstrated an increase in free-water excretion, improvement in serum sodium, modest improvements in dyspnea but no improvement in mortality. Continued clinical trials with these agents are needed to determine their specific role in the treatment of both chronic and decompensated heart failure. |
format | Text |
id | pubmed-3097052 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | SAGE-Hindawi Access to Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-30970522011-05-20 Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy Romanovsky, Adam Bagshaw, Sean Rosner, Mitchell H. Int J Nephrol Review Article Heart failure is one of the most common chronic medical conditions in the developed world. It is characterized by neurohormonal activation of multiple systems that can lead to clinical deterioration and significant morbidity and mortality. In this regard, hyponatremia is due to inappropriate and continued vasopressin activity despite hypoosmolality and volume overload. Hyponatremia is also due to diuretic use in an attempt to manage volume overload. When hyponatremia occurs, it is a marker of heart failure severity and identifies patients with increased mortality. The recent introduction of specific vasopressin-receptor antagonists offers a targeted pharmacological approach to these pathophysiological derangements. Thus far, clinical trials with vasopressin-receptor antagonists have demonstrated an increase in free-water excretion, improvement in serum sodium, modest improvements in dyspnea but no improvement in mortality. Continued clinical trials with these agents are needed to determine their specific role in the treatment of both chronic and decompensated heart failure. SAGE-Hindawi Access to Research 2011-04-18 /pmc/articles/PMC3097052/ /pubmed/21603106 http://dx.doi.org/10.4061/2011/732746 Text en Copyright © 2011 Adam Romanovsky et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Romanovsky, Adam Bagshaw, Sean Rosner, Mitchell H. Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy |
title | Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy |
title_full | Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy |
title_fullStr | Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy |
title_full_unstemmed | Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy |
title_short | Hyponatremia and Congestive Heart Failure: A Marker of Increased Mortality and a Target for Therapy |
title_sort | hyponatremia and congestive heart failure: a marker of increased mortality and a target for therapy |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3097052/ https://www.ncbi.nlm.nih.gov/pubmed/21603106 http://dx.doi.org/10.4061/2011/732746 |
work_keys_str_mv | AT romanovskyadam hyponatremiaandcongestiveheartfailureamarkerofincreasedmortalityandatargetfortherapy AT bagshawsean hyponatremiaandcongestiveheartfailureamarkerofincreasedmortalityandatargetfortherapy AT rosnermitchellh hyponatremiaandcongestiveheartfailureamarkerofincreasedmortalityandatargetfortherapy |